Trials / Completed
CompletedNCT05216497
Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- Valenta Pharm JSC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to investigate the efficacy of Ingavirin®, 90 mg capsules in achieving clinical improvement of novel coronavirus disease (COVID-19) symptoms. A secondary goal of this study is to evaluate the safety of Ingavirin®, 90 mg capsules in patients with COVID-19 infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ingavirin®, 90 mg capsules | 90-180 mg/day for 7 days on top of standard therapy |
| DRUG | Placebo | 1-2 capsules for 7 days on top of standard therapy |
Timeline
- Start date
- 2021-10-06
- Primary completion
- 2022-01-12
- Completion
- 2022-04-25
- First posted
- 2022-01-31
- Last updated
- 2023-07-27
Locations
14 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05216497. Inclusion in this directory is not an endorsement.